ERBB2 and glioblastoma: Thus, in the Phase I clinical trials of HER2-specific CAR T-cells, a partial response to the therapy was shown in patients with progressive glioblastoma; the median OS was 11.1 months after the first injection of T-cells and 24.5 months from the moment of diagnosis [167].